Chicago
-
ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more
Breast cancer drugs and cell therapies were prominent in this year’s annual meeting of the American Society of Clinical Oncology. Here’s a recap of some of the news highlights from the biggest cancer conference of the year.
-
PMV’s ASCO data show signs of drugging ‘undruggable’ p53 protein across tumor types
PMV Pharmaceuticals has its first clinical data showing that its lead therapeutic candidate can hit p53, a tumor-suppressing protein long thought to be undruggable. After reporting the preliminary data during ASCO, PMV said it plans to continue the Phase 1 study with the goal of advancing to Phase 2 early next year.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
AstraZeneca, Daiichi Sankyo have high hopes for drug that goes low in breast cancer
During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a group of patients previously thought to be out of reach for a targeted therapy. The results suggest use of this FDA-approved drug could significantly expand to more breast cancer patients.
-
Gilead offers more detail on breast cancer drug’s trial results. Is it enough?
Gilead Sciences has more detail about breast cancer drug Trodelvy, a blockbuster hopeful it acquired two years ago. Additional data from a pivotal study were presented during the annual meeting of the American Society of Clinical Oncology and they still leave many questions unanswered.
-
ASCO 2022 ahead: Clinical trial updates and data readouts to watch for
The American Society of Clinical Oncology’s annual meeting begins this week, including the presentation of more than 2,800 abstracts. Amgen, Roche, and Sierra Oncology are among the companies with key presentations at this year’s gathering.
-
Artificial Intelligence, BioPharma
Takeda returns to Evozyne’s AI tech, seeking novel proteins for next-gen gene therapies
Evozyne uses artificial intelligence and machine learning to design novel proteins that can be used in gene therapies. The new agreement with Takeda Pharmaceutical covers the development of proteins that can be used in gene therapies for rare diseases.
-
Health IT, Devices & Diagnostics, Health Tech
Digital tech for mental care grows as way to help patients navigate health deserts
The need for mental health services continues to strain the ability of the healthcare system to respond. New technologies are helping to improve patient access to care, and a panel at the MedCity INVEST conference in Chicago discussed the challenges and opportunities for these services.
-
As cash keeps pouring into health startups, VC firms work to stay disciplined
Venture capital investment in healthcare startups is continuing at a steady pace. Is it too much? Is a correction coming? Three investors offered their perspectives during a panel discussion at MedCity News’s INVEST conference in Chicago.
-
How payers are playing a part in new value-based outcomes strategies
Value-based healthcare puts the focus on patient outcomes, but payers have a part to play as well. A panel at MedCity News’ INVEST conference discussed how reimbursement strategies can improve patient care and reduce costs.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
Today’s the last day to register for INVEST and save $300
Join active investors and healthcare’s most promising entrepreneurs who are focused on solving some of the greatest challenges across the health ecosystem.
-
Diagnostic startups: Time is running out to apply to INVEST Pitch Perfect
The point of care diagnostics and testing market has climbed dramatically with the rise of the Covid-19 public health crisis. We’re seeking applications for diagnostics startups who would like to take part in INVEST Pitch Perfect Diagnostics 2.0 track at the conference, scheduled to take place March 28-30 in Chicago.
-
FDA has no appetite for Levo’s metabolic disorder drug and asks for new trial
The FDA rejected the new drug application for a Levo Therapeutics treatment for the rare metabolic disorder Prader-Willi syndrome. According to Levo, the agency said the data submitted were insufficient to support approval and the regulator wants the company to run another clinical trial.
-
Neuro startup Vanqua Bio emerges with $85M and a first focus on Parkinson’s
Vanqua Bio aims to treat rare form of Parkinson’s disease by boosting activity of an enzyme that is deficient in patients who have a particular genetic mutation. With $85 million in Series B financing, the biotech startup, which is based on Northwestern University research, aims to reach human testing within two years.
-
Leading hardtech innovation center mHUB opens MedTech accelerator for medical device startups
The mHUB MedTech Accelerator is a six-month program, based in Chicago, run in partnership with Baxter and Edward-Elmhurst Health Venture Capital. The application deadline is Monday, August 23.
-
Ipsen bets on Exicure’s tech as better way to deliver neuro drugs deep into the brain
Ipsen is shoring up its neuroscience pipeline via a deal that gives it the option to license drugs that Exicure is developing for Huntington’s disease and Angelman syndrome. The programs are based on Exicure’s proprietary technology that produces nucleic acid therapies capable of delivery deep into the brain.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
